![](https://www.canaan.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBkUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--b0d6e1decce4ddf72411c1f492b1161f02b30852/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9VWTI5dFltbHVaVjl2Y0hScGIyNXpld2M2QzNKbGMybDZaVWtpQ1RVeE1sNEdPZ1pGVkRvSmRISnBiVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--227fdc48d0cc0381319025b1f375233c6a320fb3/bipar.png)
BiPar Sciences, Inc.
BiPar is developing a potential new class of tumor-selective drugs designed to meet the unmet needs of cancer patients. BiPar was named among FierceBiotech’s ‘Top 20 venture capital deals of 2008'
Partner
Wende HuttonInvestment
Series A